Janumet Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Alerts
• Clinical Trials
• Forums

Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)
Conditions:   Diabetes;   Diabetes Mellitus, Type 2 Interventions:   Drug: Semaglutide 0.5 mg;   Drug: Semaglutide 1.0 mg;   Drug: Sitagliptin placebo;   Drug: Sitagliptin;   Drug: Semaglutide placebo 0.5 mg;   Drug: Semaglutide placebo 1.0 mg Sponsor:   Novo Nordisk A/S Not yet recruiting - verified February 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 17, 2017 Category: Research Source Type: clinical trials